Evaluation of Topical Application of BMX-010 in Subjects With Rosacea

October 15, 2026 updated by: BioMimetix JV, LLC

An Exploratory Trial to Evaluate the Clinical Effectiveness of a Topical Application of BMX-010 in Subjects With Rosacea

This is an exploratory Phase 2 trial of BMX-010 in patients with Rosacea which will be conducted in two parts. Up to 210 subjects with Rosacea will be enrolled.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug. Up to 60 subjects will be enrolled in this part.

Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo. Up to 150 subjects will be enrolled in this part.

In both parts, adult subjects with Rosacea will be enrolled.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Englewood, Colorado, United States, 80113
        • Colorado Skin Care

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male or female, at least 18 years of age;
  2. A clinical diagnosis of mild to severe facial rosacea;
  3. Screening and Baseline IGA score > 2 (greater than or equal to 2);
  4. A minimum Clinician Erythema Assessment (CEA) score of 2 at Screening and at Baseline Visits (prior to the investigational product application);
  5. Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
  6. Candidate for topical treatment of Rosacea;
  7. If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup;
  8. Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
  9. Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
  10. Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
  11. Ability to understand and provide written informed consent.

Exclusion Criteria:

  1. Any dermatological conditions on the face that could interfere with clinical evaluations;
  2. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
  3. Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
  4. Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
  5. Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
  6. Use of medicated make-up (including anti-aging make-up) throughout the study;
  7. Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact rosacea, 4) immunosuppressive agents, or immunomodulators;
  8. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics;
  9. Use of medicated cleansers on the face (throughout the study);
  10. Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
  11. Systemic or skin infection requiring antimicrobial therapy;
  12. Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
  13. Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
  14. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
  15. Active drug or alcohol dependence;
  16. Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
  17. Previous clinical trial participation for the indication being treated in this protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BMX-010 0.03%

Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.

Safety and efficacy of BMX-010 in topical treatment of rosacea.

Experimental: BMX-010 0.1%

Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.

Safety and efficacy of BMX-010 in topical treatment of rosacea.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Treatment Success Rate
Time Frame: 43 days

The percentage of subjects will be reported that experience a clinically meaningful treatment success, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade from the baseline assessment prior to treatment to the final assessment two weeks after dosing ends (Day 43).

43 days
Clinical Erythema Assessment (CEA): Clinically Meaningful Erythema Reduction Rate
Time Frame: 43 days

Assessed by number of participants with at least a 2-point reduction in Clinical Erythema Assessment (CEA) grade from the baseline score prior to treatment to a final assessment two weeks after dosing ends (Day 43).

43 days
Investigator Global Assessment (IGA) Grade: Rosacea Severity Change Over Treatment Period
Time Frame: 28 days

The Investigator Global Assessment (IGA) grade, which will be assessed weekly, is a clinical assessment of disease severity. Scores range from 0 (clear) - 4 (severe). The change in IGA score from Baseline to 28 days of treatment will be reported.

28 days
Clinical Erythema Assessment (CEA): Erythema Severity Change Over Treatment Period
Time Frame: 28 days

The Clinical Erythema Assessment (CEA) grade will be assessed weekly. Grades range from 0 = clear/no erythema to 4 = severe/fiery red erythema. The change in CEA score from Baseline to 28 days of treatment will be reported.

28 days
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Reduction During Treatment
Time Frame: 28 days

The percentage of subjects will be reported that experience a clinically meaningful rosacea reduction, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade over the treatment period of 28 days.

28 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Photography Documenting Rosacea Symptoms in Patients Treated With BMX-010
Time Frame: 43 days

If consented by the patient, photos will be taken at each study visit. The number of patients photographed will be reported.

43 days
Change in Number of Inflammatory Papules/Pustules From Baseline to 43 Day Follow-up.
Time Frame: 43 days

Inflammatory lesions will be counted at each study visit. The mean percent change in inflammatory papules/pustules counts from baseline to the final (day 43) follow-up will be reported.

43 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2019

Primary Completion (Actual)

July 2, 2019

Study Completion (Actual)

February 13, 2023

Study Registration Dates

First Submitted

November 15, 2018

First Submitted That Met QC Criteria

November 26, 2018

First Posted (Actual)

November 28, 2018

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

October 15, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • BMX-DERM-202

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.